Form 4: Disc Medicine Director William White Executes Stock Sales Under 10b5-1 Plan

Director William Richard White sold shares of Disc Medicine (IRON) on July 1, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On July 1, 2024, William Richard White, a director of Disc Medicine, Inc. (IRON), executed transactions involving the company's common stock.
• These transactions included the exercise of stock options and subsequent sales of the acquired shares.
• The sales were conducted under a Rule 10b5-1 trading plan adopted on December 13, 2023.
• A total of 201 shares were acquired through option exercise at a price of $9.86 per share.
• Simultaneously, 201 shares were disposed of through multiple sales at weighted average prices of $45.0706, $45.9159, and $46.4486.
• The director now directly owns zero shares of common stock.
• The director still owns 2,809 stock options.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports routine stock sales under a pre-arranged trading plan. There is no indication of positive or negative implications for the company.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It's common for executives and directors to utilize 10b5-1 trading plans to sell shares over time to avoid accusations of trading on inside information.

Comparison to Industry Standards

• Insider trading activity is closely monitored across the pharmaceutical industry.
• Companies like Pfizer, Merck, and Johnson & Johnson also have executives who regularly file Form 4s for stock transactions.
• The use of 10b5-1 plans is a standard practice to ensure compliance with insider trading regulations.
• The size and frequency of these transactions are typical for directors managing their personal portfolios.

Key Dates